Medium term efficacy and safety of adalimumab therapy in patients with Crohn's disease. national data from Hungary
Z Czegledi, P Miheller, T Molnar, L Lakatos, A Vincze, K Palatka, B Gasztonyi, A Salamon, G Horvath, T Szamosi, Z Tulassay, M Papp, L Kiss, J Papp, P Lakatos · Zeitschrift für Gastroenterologie · 2010 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background/Aims: Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor with proven efficacy in the treatment of Crohn's disease in clinical trials. In the present study our aim was to investigate the short and medium term efficacy and side effects during induction and maintenance adalimumab therapy in patients with Crohn's disease in specialized centers approved for biological therapy in Hungary until the 1st of November 2009. Methods: Data of 139 CD patients were analyzed. (male/female: 61/78, mean age: 34.4 years, duration: 10.5 years). Indication for biologic therapy was active lumin…
